UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
January 26, 2016
Date of Report
TAPIMMUNE INC.
(Exact name of registrant as specified in its charter)
Nevada | 000-27239 | 45-4497941 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
50 N. Laura Street, Suite 2500 Jacksonville, FL |
98102 | |||
(Address of principal executive offices) | (Zip Code) |
(206) 504-7278
Registrants telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 27, 2016, TapImmune Inc. (the Company), announced that Frederick G. Wasserman, age 60, of Pennington, New Jersey, has been appointed to the Board of Directors of the Company. A copy of the press release is attached to this Report as Exhibit 99.1. Mr. Wassermans appointment was effective on July 26, 2016.
Mr. Wasserman is a business executive with over 35 years of business experience, having served at various companies in roles including Chief Executive Officer, President, Chief Operating Officer and Chief Financial Officer. He is currently the President of FGW Partners LLC, Pennington, NJ, where he has been employed since 2007. He currently serves on the boards of directors of several public companies.
Mr. Wasserman was employed as a certified public accountant from 1976 to 1989. He earned a Bachelor of Science degree from The Wharton School at The University of Pennsylvania in 1976.
Pursuant to the Director Compensation Plan previously approved by the Board of Directors, in connection with his appointment to the Board Mr. Wasserman was granted an option to purchase 150,000 shares of the common stock of the Company under the 2014 Omnibus Stock Ownership Plan, at a price equal to the closing price of the common stock on the date of his appointment, with such options to vest in in equal monthly installments over the following 24 months.
Item 9.01 Financial Statements and Exhibits.
Exhibit 99.1 | Press release issued on January 27, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TAPIMMUNE INC. | ||||||
Date: January 27, 2016 | By: | /s/ Glynn Wilson | ||||
Name: | Glynn Wilson | |||||
Title: | Chairman and CEO |
Exhibit 99.1
TapImmune Appoints Frederick G. Wasserman to its Board of Directors
Accomplished Financial Director & CFO of Public Companies
PR Newswire
JACKSONVILLE, Florida, January 27, 2016
JACKSONVILLE, Florida, January 27, 2016 /PRNewswire/
TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, is pleased to announce the appointment of Frederick G. Wasserman to its Board as an Independent Director.
Frederick (Rick) is an accomplished Board Director with 35 years of business experience. He has served during his career as President, COO and CFO of entrepreneurial, middle-market companies. Rick has a strong financial background which he has successfully focused on all aspects of company operations including cash flow, profitability and equity valuation. He has served as a member of Audit and Corporate Governance Committees for public companies in the U.S. and Europe. In his role as President of FGW Partners LLC, Pennington, New Jersey, he has assisted small and micro-cap companies at transitional points in their evolutions. This has included focus on corporate governance, investment analysis and liquidity management, as well as general financial and operational issues.
Rick was a Certified Public Accountant who held staff positions through Audit Manager for three accounting firms. He has a B.S. in Economics from the Wharton School, University of Pennsylvania, PA.
Dr. Glynn Wilson, Chairman & CEO of TapImmune, stated, We welcome Rick to the TapImmune Board of Directors. His strong financial background and success in working as an Officer or as a Board member of a variety of entrepreneurial public companies will be a significant asset to TapImmune in the next phase of our Companys growth.
About TapImmune Inc.
TapImmune Inc. is an immune-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastatic disease. The Companys peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Companys technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Companys website at http://www.tapimmune.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Companys expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are forward-looking statements. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Companys most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
CONTACTS:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1-(866)-359-7541
SOURCE TapImmune Inc.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.